

**SANDOSTATIN
(octreotide)****RATIONALE FOR INCLUSION IN PA PROGRAM****Background**

Sandostatin (octreotide) exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide (1).

Regulatory Status

FDA-approved indication: Sandostatin is indicated for: (1)

- Acromegaly
- Diarrhea or flushing associated with carcinoid tumors
- Diarrhea associated with VIP-secreting tumors).

Summary

Sandostatin (octreotide) exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide (1).

Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Sandostatin while maintaining optimal therapeutic outcomes.

References

1. Sandostatin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2023.